Wegovy weight loss pill launches in UK via private prescription, with NHS availability still under consideration

Unbiased summary

The pill form of Wegovy, containing semaglutide, became available in the UK from today via private prescription through high street and online pharmacies. The Medicines and Healthcare products Regulatory Agency licensed it last month. It is not yet available on the NHS. The pill works similarly to the existing weekly injection but is taken daily on an empty stomach, does not require refrigeration, and has similar eligibility criteria and side effects. Lower-dose pills cost approximately £80-£100 per month, rising to over £200 at higher doses. Demand is expected to be high, with some online pharmacies reporting waiting lists exceeding 100,000. Regulators and pharmacists have raised concerns about counterfeit and unlicensed versions being sold online. The drug must be prescribed alongside dietary and exercise support.

Generated with Claude Sonnet 4.6

Coverage by outlet

The Mirror centre-left

Angle The Mirror foregrounds public health warnings and consumer safety risks, framing the launch primarily as a concern rather than a celebration.

Bias The Mirror leads with the word 'Warning' in its headline, immediately priming readers toward risk rather than neutral reporting of a product launch. It gives significant prominence to counterfeit dangers and the pharmacists' poll showing 97% concern, which, while factually valid, receives more editorial weight than the drug's efficacy or patient access benefits. It also notably includes the detail about muscle and bone density loss from unsupported use, a medically important but selectively emphasised negative that other outlets downplay or omit.

Warning as Wegovy pill goes on sale in Britain for the first time from today

BBC News centre-left

Angle The BBC takes a neutral, consumer-information approach, presenting the launch as a factual explainer without strong editorial framing.

Bias The BBC's coverage is the most balanced of the three, focusing on practical information such as eligibility, cost, side effects, and the difference between pill and injection formats. It does not sensationalise demand or unduly emphasise risks. One minor omission is that it gives less prominence to the counterfeit drug concern than the Mirror, and less promotional weight to personal success stories than the Mail, keeping it broadly neutral. It does not stray significantly from the objective facts.

Wegovy weight loss pill now available in UK - here's what you need to know

Daily Mail right

Angle The Daily Mail frames the launch as an exciting consumer opportunity, leading with personal weight-loss success stories to generate enthusiasm and demand.

Bias The Mail's headline and opening section are notably promotional in tone, using phrases like 'game-changing moment for slimmers' and foregrounding American patients' positive anecdotes ahead of any clinical or regulatory context. It emphasises waiting lists of 100,000 as evidence of desirability rather than a potential supply concern, and the mention of side effects, counterfeit risks, and the requirement for dietary support is significantly downplayed compared to the objective record. The use of personal testimonials from US patients as a primary narrative device introduces anecdotal evidence that carries more persuasive than informational weight.

We've already lost 15lb on the new Wegovy weight-loss pill that's cheaper than jabs. It launches TODAY - here's everything you need to know about how to get it, side effects and trick to turbocharge weight loss with no extra effort